Skip to main content

Advertisement

Springer Nature Link
Log in

Food protein-derived bioactive peptides in management of type 2 diabetes

  • Review
  • Published:
European Journal of Nutrition Aims and scope Submit manuscript

Abstract

Background

Type 2 diabetes (T2D), one of the major common human health problems, is growing at an alarming rate around the globe. Alpha-glucosidase and dipeptidyl peptidase IV (DPP-IV) enzymes play a significant role in development of T2D. Hence, reduction or inhibition of their activity can be one of the important strategies in management of T2D. Studies in the field of bioactive peptides have shown that dietary proteins could be natural source of alpha-glucosidase and DPP-IV inhibitory peptides.

Purpose

The purpose of this review is to provide an overview of food protein-derived peptides as potential inhibitors of alpha-glucosidase and DPP-IV with major focus on milk proteins.

Methods

Efforts have been made to review the available information in literature on the relationship between food protein-derived peptides and T2D. This review summarizes the current data on alpha-glucosidase and dipeptidyl peptidase IV inhibitory bioactive peptides derived from proteins and examines the potential value of these peptides in the treatment and prevention of T2D. In addition, the proposed modes of inhibition of peptide inhibitors are also discussed.

Results

Studies revealed that milk and other food proteins-derived bioactive peptides play a vital role in controlling T2D through several mechanisms, such as the satiety response, regulation of incretin hormones, insulinemia levels, and reducing the activity of carbohydrate degrading digestive enzymes.

Conclusions

The bioactive peptides could be used in prevention and management of T2D through functional foods or nutraceutical supplements. Further clinical trials are necessary to validate the findings of in vitro studies and to confirm the efficiency of these peptides for applications.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. IDF (2013) IDF diabetes atlas, 6th edn. International Diabetes Federation, Brussels

    Google Scholar 

  2. King H, Aubert RE, Herman WH (1998) Global burden of diabetes, 1995–2025: prevalence, numerical estimates, and projections. Diabetes Care 21:1414–1431

    CAS  Google Scholar 

  3. UK Prospective Diabetes Study (UKPDS) Group (1998) Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 317:703–713

    Google Scholar 

  4. Tiwari A, Rao JM (2002) Diabetes mellitus and multiple therapeutic approaches of phytochemicals: present status and future prospects. Curr Sci 83:30–38

    CAS  Google Scholar 

  5. Avignon A, Radauceanu A, Monnier L (1997) Nonfasting plasma glucose is a better marker of diabetic control than fasting plasma glucose in type 2 diabetes. Diabetes Care 20:1822–1826

    CAS  Google Scholar 

  6. Abrahaamson MJ (2004) Optimal glycemic control in type 2 diabetes mellitus: fasting and postprandial glucose in context. Arch Intern Med 164:486–491

    Google Scholar 

  7. Jermendy G (2005) Can type 2 diabetes mellitus be considered preventable? Diabetes Res Clin Pract 68:S73–S81

    CAS  Google Scholar 

  8. Ben-Avraham S, Harman-Boehm I, Schwarzfuchs D (2009) Dietary strategies for patients with type 2 diabetes in the era of multi-approaches review and results from the dietary intervention randomized controlled trial (DIRECT). Diabetes Res Clin Pract 86:S41–S48

    CAS  Google Scholar 

  9. Bantle Jp, Wylie-Rosett J, Albright AL, Apovian CM, Clark NG, Franz MJ (2008) Nutrition recommendations and interventions for diabetes: a position statement of the American diabetes association. Diabetes Care 31:S61–S78

    CAS  Google Scholar 

  10. Hawley JA, Gibala MJ (2012) What’s new since Hippocrates? Preventing type 2 diabetes by physical exercise and diet. Diabetologia 55:535–539

    CAS  Google Scholar 

  11. Holman RR, Cull CA, Turner RC (1999) A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (UK Prospective Diabetes Study 44). Diabetes Care 22:960–964

    CAS  Google Scholar 

  12. Toeller M (1994) α-Glucosidase inhibitors in diabetes: efficacy in NIDDM subjects. Eur J Clin Invest 24:31–35

    Google Scholar 

  13. Clissold SP, Edwards C (1988) A preliminary review of its pharmacodynamic and pharmacokinetics properties, and therapeutic potential. Drugs 35:214–243

    CAS  Google Scholar 

  14. Saito N, Sakai H, Sekihara H, Yajima Y (1998) Effect of an α-glucosidase inhibitor (voglibose) in combination with sulphonilureas, on glycemic control in type 2 diabetes patients. J Int Med Res 26:219–232

    CAS  Google Scholar 

  15. Bennett WL, Wilson LM, Bolen S et al (2011) Oral diabetes medications for adults with type 2 diabetes: an update. Comparative Effectiveness Rev. 27. http://www.effectivehealthcare.ahrq.gov/reports/final.cfm. Accessed 09 Nov 2014

  16. Tahrani AA, Bailey CJ, Del Prato S, Barnett AH (2011) Management of type 2 diabetes: new and future development. Lancet 378:182–197

    CAS  Google Scholar 

  17. American Diabetes Association (2015) Standards of medical care in diabetes-2015. Diabetes Care 38:S1–S98

    Google Scholar 

  18. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR (2012) Management of hyperglycemia in type 2 diabetes: a patient-centered approach position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 35:1364–1379

    CAS  Google Scholar 

  19. Agius R (2014) An update on pharmacotherapy for type 2 diabetes. Malta Med J 26:29–38

    Google Scholar 

  20. Evert AB, Boucher JL, Cypress M et al (2014) Nutrition therapy recommendations for the management of adults with diabetes. Diabetes Care 37(Suppl 1):S120–S143

    Google Scholar 

  21. Nongonierma AB, FitzGerald RJ (2013) Dipeptidyl peptidase IV inhibitory and antioxidative properties of milk protein-derived dipeptides and hydrolysates. Peptides 39:157–163

    CAS  Google Scholar 

  22. Kitts DD, Weiler K (2003) Bioactive proteins and peptide from food sources: application of bioprocesses used in isolation and recovery. Curr Pharm Des 9:1309–1323

    CAS  Google Scholar 

  23. Korhonen H, Pihlanto A (2006) Bioactive peptides: production and functionality. Int Dairy J 16:945–960

    CAS  Google Scholar 

  24. Phelan M, Kerins D (2011) The potential role of milk-derived peptides in cardiovascular disease. Food Funct 2:153–167

    CAS  Google Scholar 

  25. Tidona F, Criscione A, Guastella AM, Zuccaro A, Bordonaro S, Marletta D (2009) Bioactive peptides in dairy products. Ital J Anim Sci 8:315–340

    Google Scholar 

  26. Korhonen H (2009) Milk-derived bioactive peptides: from science to applications. J Funct Foods 1:177–187

    CAS  Google Scholar 

  27. Seppo L, Jauhiainen T, Poussa T, Korpela R (2003) A fermented milk high in bioactive peptides has a blood pressure lowering effect in hypertensive subjects. Am J Clin Nutr 77:326–330

    CAS  Google Scholar 

  28. Haug A, Hostmark AT, Harstad OM (2007) Bovine milk in human nutrition–a review. Lipids Health Dis 6:1–16

    Google Scholar 

  29. Ebringer L, Ferenčík M, Krajčovič J (2008) Beneficial health effects of milk and fermented dairy products-review. Folia Microbiol 53:378–394

    CAS  Google Scholar 

  30. Atanasova J, Ivanova I (2010) Antibacterial peptides from goat and sheep milk proteins. Biotechnol Biotechnol Equip 24:1799–1803

    CAS  Google Scholar 

  31. Meisel H (1998) Overview on milk protein-derived peptides. Int Dairy J 8:363–373

    CAS  Google Scholar 

  32. Ricci-Cabello I, Olalla Herrera M, Artacho R (2012) Possible role of milk derived bioactive peptides in the treatment and prevention of metabolic syndrome. Nutr Rev 70:241–255

    Google Scholar 

  33. Lacroix IM, Li-Chan ECY (2013) Inhibition of dipeptidyl peptidase (DPP)-IV and α-glucosidase activities by pepsin-treated whey proteins. J Agric Food Chem 61:7500–7506

    CAS  Google Scholar 

  34. Konrad B, Anna D, Marek S, Marta P, Aleksandra Z, Jozefa C (2014) The evaluation of dipeptidyl peptidase (DPP)-IV, α-Glucosidase and angiotensin converting enzyme (ACE) inhibitory activities of whey proteins hydrolyzed with serine protease isolated from asian pumpkin (Cucurbita ficifolia). Int J Pept Res Ther 20:483–491

    CAS  Google Scholar 

  35. Frid AH, Nilsson M, Holst JJ, Björck IME (2005) Effect of whey on blood glucose and insulin responses to composite breakfast and lunch meals in type 2 diabetic subjects. Am J Clin Nutr 82:69–75

    CAS  Google Scholar 

  36. Manders RJF, Wagenmakers AJM, Koopman R (2005) Co-ingestion of a protein hydrolysate and amino acid mixture with carbohydrate improves plasma glucose disposal in patients with type 2 diabetes. Am J Clin Nutr 82:76–83

    CAS  Google Scholar 

  37. Korhonen H, Pihlanto A (2007) Technological options for the production of health-promoting proteins and peptides derived from milk and colostrum. Curr Pharm Des 13:829–843

    CAS  Google Scholar 

  38. Jakubowicz D, Froy O (2013) Biochemical and metabolic mechanisms by which dietary whey protein may combat obesity and type 2 diabetes. J Nutr Biochem 24:1–5

    CAS  Google Scholar 

  39. Graf S, Egert S, Heer M (2011) Effects of whey protein supplements on metabolism: evidence from human intervention studies. Curr Opin Clin Nutr Metab Care 14:569–580

    CAS  Google Scholar 

  40. Boirie Y, Dangin M, Gachon P, Vasson MP, Maubois JL, Beaufrère B (1997) Slow and fast dietary proteins differently modulate postprandial protein accretion. Proc Natl Acad Sci 94:14930–14935

    CAS  Google Scholar 

  41. Dangin M, Boirie Y, Garcia-Rodenas C, Gachon P, Fauquant J, Callier P (2001) The digestion rate of protein is an independent regulating factor of postprandial protein retention. Am J Physiol Endocrinol Metab 280:E340–E348

    CAS  Google Scholar 

  42. Nilsson M, Stenberg M, Frid AH, Holst JJ, Björck IME (2004) Glycemia and insulinemia in healthy subjects after lactose-equivalent meals of milk and other food proteins: the role of plasma amino acids and incretins. Am J Clin Nutr 80:1246–1253

    CAS  Google Scholar 

  43. Nilsson M, Holst JJ, Björck IM (2007) Metabolic effects of amino acid mixtures and whey protein in healthy subjects: studies using glucose-equivalent drinks. Am J Clin Nutr 85:996–1004

    CAS  Google Scholar 

  44. Calbet JA, Holst JJ (2004) Gastric emptying, gastric secretion and enterogastrone response after administration of milk proteins or their peptide hydrolysates in humans. Eur J Nutr 43:127–139

    CAS  Google Scholar 

  45. McGregor RA, Poppitt SD (2013) Milk protein for improved metabolic health:a review of the evidence. Nutr Metab 10:46

    CAS  Google Scholar 

  46. Pistrosch F, Natali A, Hanefeld M (2011) Is hyperglycemia a cardiovascular risk factor? Diabetes Care 34:S128–S131

    Google Scholar 

  47. Gerich JE (2003) Clinical significance, pathogenesis, and management of postprandial hyperglycemia. Arch Intern Med 16:1306–1316

    Google Scholar 

  48. Akhavan T, Luhovyy BL, Brown PH, Cho CE, Anderson GH (2010) Effect of premeal consumption of whey protein and its hydrolysate on food intake and postmeal glycemia and insulin responses in young adults. Am J Clin Nutr 91:966–975

    CAS  Google Scholar 

  49. Pal S, Ellis V (2010) The acute effects of four protein meals on insulin, glucose, appetite and energy intake in lean men. Br J Nutr 104:1241–1248

    CAS  Google Scholar 

  50. Claessens M, Calame W, Siemensma AD, Van Baak MA, Saris WHM (2009) The effect of different protein hydrolysate/carbohydrate mixtures on postprandial glucagon and insulin responses in healthy subjects. Eur J Clin Nutr 63:48–56

    CAS  Google Scholar 

  51. Petersen BL, Ward LS, Bastian ED, Jenkins AL, Campbell J, Vuksan V (2009) A whey protein supplement decreases post-prandial glycemia. Nutr J 8:1475–2891

    Google Scholar 

  52. Drucker DJ (2006) Enhancing the action of incretin hormones: a new whey forward? Endocrinology 147:3171–3172

    CAS  Google Scholar 

  53. Manders RJF, Praet SFE, Meex RCR, Koopman R, de Roos AL, Wagenmakers AJM, Saris WHM, van Loon LJ (2006) Protein hydrolysate/leucine co-ingestion reduces the prevalence of hyperglycemia in type 2 diabetic patients. Diabetes Care 29:2721–2722

    CAS  Google Scholar 

  54. Fromentin G, Darcel N, Chaumontet C, Marsset-Baglieri A, Nadkarni N, Tomé D (2012) Peripheral and central mechanisms involved in the control of food intake by dietary amino acids and proteins. Nutr Res Rev 25:29–39

    CAS  Google Scholar 

  55. Jones KW, Eller LK, Parnell JA, Doyle-Baker PK, Edwards AL, Reimer RA (2013) Effect of a dairy and calcium rich diet on weight loss and appetite during energy restriction in overweight and obese adults: a randomized trial. Eur J Clin Nutr 67:371–376

    CAS  Google Scholar 

  56. Diepvens K, Häberer D, Westerterp-Plantenga M (2008) Different proteins and biopeptides differently affect satiety and anorexigenic/orexigenic hormones in healthy humans. Int J Obes 32:510–518

    CAS  Google Scholar 

  57. Lorenzen J, Frederiksen R, Hoppe C, Hvid R, Astrup A (2012) The effect of milk proteins on appetite regulation and diet-induced thermogenesis. Eur J Clin Nutr 66:622–627

    CAS  Google Scholar 

  58. Hernández-Ledesma B, García-Nebot MJ, Fernández-Tomé S, Amigo L, Recio I (2013) Dairy protein hydrolysates: peptides for health benefits. Int Dairy J 38:82–100. doi:10.1016/j.idairyj.2013.11.004

    Google Scholar 

  59. Hall WL, Millward DJ, Long SJ, Morgan LM (2003) Casein and whey exert different effects on plasma amino acid profiles, gastrointestinal hormone secretion and appetite. Br J Nutr 89:239–248

    CAS  Google Scholar 

  60. Kazafeos K (2011) Incretin effect: GLP-1, GIP, DPP4. Diabetes Res Clin Pract 93(Suppl 1):S32–S36

    CAS  Google Scholar 

  61. Salehi A, Gunnerud U, Muhammed SJ, Ostman E, Holst JJ, Bjorck I (2012) The insulinogenic effect of whey protein is partially mediated by a direct effect of amino acids and GIP on beta-cells. Nutr Metab 9:48

    CAS  Google Scholar 

  62. Veldhorst MA, Nieuwenhuizen AG, Hochstenbach-Waelen A, van Vught AJ, Westerterp KR, Engelen MP (2009) Dose-dependent satiating effect of whey relative to casein or soy. Physiol Behav 96:675–682

    CAS  Google Scholar 

  63. Nauck MA, Vilsboll T, Gallwitz B, Garber A, Madsbad S (2009) Incretin-based therapies: viewpoints on the way to consensus. Diabetes Care 32(Suppl 2):S223–S231

    CAS  Google Scholar 

  64. Portha B, Tourrel-Cuzin C, Movassat J (2011) Activation of the GLP-1 receptor signaling pathway: a relevant strategy to repair a deficient beta-cell mass. Exp Diabetes Res. doi:10.1155/2011/376509

    Google Scholar 

  65. Halton TL, Hu FB (2004) The effects of high protein diets on thermogenesis, satiety and weight loss: a critical review. J Am Coll Nutr 23:373–385

    Google Scholar 

  66. Anderson GH, Tecimer SN, Shah D, Zafar TA (2004) Protein source, quantity, and time of consumption determine the effect of proteins on short-term food intake in young men. J Nutr 134:3011–3015

    CAS  Google Scholar 

  67. Yudkoff M, Daikhin Y, Nissim I, Horyn O, Luhovyy B, Lazarow A (2005) Brain amino acid requirements and toxicity: the example of leucine. J Nutr 135:1531S–1538S

    CAS  Google Scholar 

  68. Morrison CD, Xi X, White CL, Ye J, Martin RJ (2007) Amino acids inhibit Agrp gene expression via an mTOR-dependent mechanism. Am J Physiol Endocrinol Metab 293:E165–E171

    CAS  Google Scholar 

  69. Lacroix IME, Li-Chan ECY (2012) Dipeptidyl peptidase-IV inhibitory activity of dairy protein hydrolysates. Int Dairy J 25:97–102

    CAS  Google Scholar 

  70. Tulipano G, Sibilia V, Caroli AM, Cocchi D (2011) Whey proteins as source of dipeptidyl dipeptidase IV (dipeptidyl peptidase-4) inhibitors. Peptides 32:835–838

    CAS  Google Scholar 

  71. Uenishi H, Kabuki T, Seto Y, Serizawa A, Nakajima H (2012) Isolation and identification of casein-derived dipeptidyl-peptidase 4 (DPP-4)-inhibitory peptide LPQNIPPL from gouda-type cheese and its effect on plasma glucose in rats. Int Dairy J 22:24–30

    CAS  Google Scholar 

  72. Yao Y, Sang W, Zhou M, Ren G (2010) Antioxidant and alpha-glucosidase inhibitory activity of colored grains in China. J Agric Food Chem 58:770–774

    CAS  Google Scholar 

  73. Jaiswal N, Srivastava SP, Bhatia V, Mishra A, Sonkar AK (2012) Inhibition of alpha-glucosidase by acacia nilotica prevents hyperglycemia along with improvement of diabetic complications via aldose reductase inhibition. J Diabetes Metab 6:1–7

    Google Scholar 

  74. Apostolidis E, Kwon YI, Ghaedian R, Shetty K (2007) Fermentation of milk and soymilk by Lactobacillus bulgaricus and Lactobacillus acidophilus enhances functionality for potential dietary management of hyperglycemia and hypertension. Food Biotechnol 21:217–236

    CAS  Google Scholar 

  75. Slama G, Elgrably F, Mbemba J, Larger E (2006) Postprandial glycaemia:a plea for the frequent use of delta postprandial glycaemia in the treatment of diabetic patients. Diabetes Metab 32:187–192

    CAS  Google Scholar 

  76. Lee A, Patrick P, Wishart J, Horowitz M, Morley JE (2002) The effects of miglitol on glucagon-like peptide-1 secretion and appetite sensations in obese type 2 diabetics. Diabetes Obes Metab 4:329–335

    CAS  Google Scholar 

  77. Yusuke Moritoh, Takeuchi Koji, Hazama Masatoshi (2009) Voglibose, an alpha-glucosidase inhibitor, to increase active glucagon-like peptide-1 levels. Mol Cell Pharmacol 1:188–192

    Google Scholar 

  78. Campbell LK, Baker DE, Campbell RK (2000) Miglitol: assessment of its role in the treatment of patients with diabetes mellitus. Ann Pharmacother 34:1291–1301

    CAS  Google Scholar 

  79. Krentz AJ, Bailey CJ (2005) Oral antidiabetic agents:current role in type 2 diabetes mellitus. Drugs 65:385–411

    CAS  Google Scholar 

  80. Nathan DM, Buse JB, Davidson MB, Heine RJ, Holman RR, Sherwin R, Zinman B (2006) Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 49:1711–1721

    CAS  Google Scholar 

  81. McDougall GJ, Shpiro F, Dobson P, Smith P, Blake A, Stewart D (2005) Different polyphenolic components of soft fruits inhibit α-amylase and α-glucosidase. J Agric Food Chem 53:2760–2766

    CAS  Google Scholar 

  82. da Silva Pinto M, Kwon YI, Apostolidis E, Lajolo FM, Genovese MI, Shetty K (2008) Functionality of bioactive compounds in Brazilian strawberry (Fragaria ananassa Duch.) cultivars: evaluation of hyperglycemia and hypertension potential using in vitro models. J Agric Food Chem 56:4386–4392

    Google Scholar 

  83. McCue P, Kwon YI, Shetty K (2005) Anti-amylase, anti-glucosidase and anti-angiotensin I-converting enzyme potential of selected foods. J Food Biochem 29:278–294

    CAS  Google Scholar 

  84. Matsui T, Yoshimoto C, Osajima K, Oki T, Osajima Y (1996) In vitro survey of α-glucosidase inhibitory food components. Biosci Biotechnol Biochem 60:2019–2022

    CAS  Google Scholar 

  85. Yu Z, Yin Y, Zhao W, Yu Y, Liu B, Liu J, Chen F (2011) Novel peptides derived from egg white protein inhibiting alpha-glucosidase. Food Chem 129:1376–1382

    CAS  Google Scholar 

  86. Aschenbrenner DS, Venable SJ (2009) Drug therapy in nurshing, 3rd edn. Wolters Kluwer Health, New York, pp 589–592

    Google Scholar 

  87. Ross SA, Gulve EA, Wang M (2004) Chemistry and biochemistry of type 2 diabetes. Chem Rev 104:1255–1282

    CAS  Google Scholar 

  88. Chiasson JL, Rabasa-Lhoret R (2004) Prevention of type 2 diabetes:insulin resistance and beta-cell function. Diabetes 53:S34–S38

    CAS  Google Scholar 

  89. Arungarinathan G, McKay GA, Fisher M (2011) Drugs for diabetes: part 4 acarbose. Br J Cardiol 18:78–81

    Google Scholar 

  90. Holst JJ (2004) On the physiology of GIP and GLP-1. Horm Metab Res 36:747–754

    CAS  Google Scholar 

  91. Gromada J, Rorsman P (2004) New insights into the regulation of glucagon secretion by glucagon-like peptide-1. Horm Metab Res 36:822–829

    CAS  Google Scholar 

  92. Perfetti R, Hui H (2004) The role of GLP-1 in the life and death of pancreatic beta cells. Horm Metab Res 36:804–810

    CAS  Google Scholar 

  93. Goto Y, Yamada K, Ohyama T, Matsuo T, Odaka H, Ikeda H (1995) An alpha-glucosidase inhibitor, AO-128, retards carbohydrate absorption in rats and humans. Diabetes Res Clin Pract 28:81–87

    CAS  Google Scholar 

  94. Gribble FM, Williams L, Simpson AK, Reimann F (2003) A novel glucose-sensing mechanism contributing to glucagon-like peptide-1 secretion from the GLUTag cell line. Diabetes 52:1147–1154

    CAS  Google Scholar 

  95. Tolhurst G, Reimann F, Gribble FM (2009) Nutritional regulation of glucagon-like peptide-1 secretion. J Physiol 587:27–32

    CAS  Google Scholar 

  96. Moritoh Y, Takeuchi K, Hazama M (2009) Chronic administration of voglibose, an alpha-glucosidase inhibitor, increases active glucagon-like peptide-1 levels by increasing its secretion and decreasing dipeptidyl peptidase-F4 activity in ob/ob mice. J Pharmacol Exp Ther 329:669–676

    CAS  Google Scholar 

  97. Nauck MA (1998) Glucagon-like peptide 1 (GLP-1): a potent gut hormone with a possible therapeutic perspective. Acta Diabetol 35:117–129

    CAS  Google Scholar 

  98. Bharatham K, Bharatham N, Park KH, Lee KW (2008) Binding mode analyses and pharmacophore model development for sulfonamide chalcone derivatives, a new class of α-glucosidase inhibitors. J Mol Graph Model 26:1202–1212

    CAS  Google Scholar 

  99. Matsui T, Oki T, Osajima Y (1999) Isolation and identification of peptidic α-glucosidase inhibitors derived from sardine muscle hydrolyzate. Z Naturforsch C 54:259–263

    CAS  Google Scholar 

  100. Lavigne C, Marette A, Jacques H (2000) Cod and soy proteins compared with casein improve glucose tolerance and insulin sensitivity in rats. Am J Physiol 278:E491–E500

    CAS  Google Scholar 

  101. Lavigne C, Tremblay F, Asselin G, Jaques H, Marette A (2001) Prevention of skeletal muscle insulin resistance by dietary cod protein in high fat-fed rats. Am J Physiol Endocrinol Metab 281:E62–E71

    CAS  Google Scholar 

  102. Huang FJ, Wu WT (2010) Purification and characterization of a new peptide (s-8300) from shark liver. J Food Biochem 34:962–970

    CAS  Google Scholar 

  103. Yu Z, Yin Y, Zhao W, Liu J, Chen F (2012) Anti-diabetic activity peptides from albumin against α-glucosidase and α-amylase. Food Chem 135:2078–2085

    CAS  Google Scholar 

  104. Ramchandran L, Shah NP (2009) Effect of exopolysaccharides and inulin on the proteolytic, angiotensin-I-converting enzyme- and α-glucosidase-inhibitory activities as well as on textural and rheological properties of low-fat yogurt during refrigerated storage. Dairy Sci Technol 89:583–600

    CAS  Google Scholar 

  105. Fan H, Yan S, Stehling S, Marguet D, Schuppan D, Reutter W (2003) Dipeptidyl peptidase IV/CD26 in T cell activation, cytokine secretion and immunoglobulin production. Adv Exe Med Biol 524:165–174

    CAS  Google Scholar 

  106. Shubrook J, Colucci R, Guo A, Schwartz F (2011) Saxagliptin: a selective DPP-4 inhibitor for the treatment of type 2 diabetes mellitus. Clin Med Insights Endocrinol Diabetes 4:1–12

    CAS  Google Scholar 

  107. Kushner P, Gorrell M (2010) DPP-4 inhibitors in type 2 diabetes: importance of selective enzyme inhibition and implications for clinical use. J Fam Pract 59(2):1

    Google Scholar 

  108. Wang XM, Yu DM, McCaughan GW (2005) Fibroblast activation protein increases apoptosis, cell adhesion, and migration by the LX-2 human stellate cellline. Hepatology 42:935–945

    CAS  Google Scholar 

  109. Amerongen AV, Beelen MJC, Wolbers LAM, Gilst WH, Buikema JH, Nelissen JWPM (2009) Egg protein hydrolysates. WO 2009/128713 A1 (Patent)

  110. Li-Chan ECY, Huang SL, Jao CL, Ho KP, Hsu KC (2012) Peptides derived from Atlantic salmon skin gelatin as dipeptidyl-peptidase IV inhibitors. J Agric Food Chem 60:973–978

    CAS  Google Scholar 

  111. Huang SL, Jao CL, Ho KP, Hsu KC (2012) Dipeptidyl peptidase IV inhibitory activity of peptides derived from tuna cooking juice hydrolysates. Peptides 35:114–121

    CAS  Google Scholar 

  112. Velarde-Salcedo AJ, Barrera-Pacheco A, Lara-González S, Montero-Morán GM, Díaz-Gois A, Gonzá lez de Mejia E, Barba de la Rosa A (2013) In vitro inhibition of dipeptidyl peptidase IV by peptides derived from the hydrolysis of amaranth (Amaranthus hypochondriacus L.) proteins. Food Chem 136:758–764

    CAS  Google Scholar 

  113. Hatanaka T, Inoue Y, Arima J, Kumagai Y, Usuki H, Kawakami K, Kimura M, Mukaihara T (2012) Production of dipeptidyl peptidase IV inhibitory peptides from defatted rice bran. Food Chem 134:797–802

    CAS  Google Scholar 

  114. Mochida T, Hira T, Hara H (2010) The corn protein, zein hydrolysate, administered into the ileum attenuates hyperglycemia via its dual action on glucagon-like peptide-1 secretion and dipeptidyl peptidase-IV activity in rats. Endocrinology 151:3095–3104

    CAS  Google Scholar 

  115. Tulipano G, Cocchi D, Caroli AM (2012) Comparison of goat and sheep β-lactoglobulin to bovine β-lactoglobulin as potential source of dipeptidyl peptidase IV (DPP-4) inhibitors. Int Dairy J 24:97–101

    CAS  Google Scholar 

  116. Uchida M, Ohshiba Y, Mogami O (2011) Novel dipeptidyl peptidase-4-inhibiting peptide derived from β-lactoglobulin. J Pharmacol Sci 117:63–66

    CAS  Google Scholar 

  117. Lacroix IME, Li Chan ECY (2012) Evaluation of the potential of dietary proteins as precursors of dipeptidyl peptidase (DPP)-IV inhibitors by an in silico approach. J Funct Food 4:403–422

    CAS  Google Scholar 

  118. Nongonierma AB, FitzGerald RJ (2013) Dipeptidyl peptidase IV inhibitory properties of a whey protein hydrolysate: influence of fractionation, stability to simulated gastrointestinal digestion and food-drug interaction. Int Dairy J 32:33–39

    CAS  Google Scholar 

  119. Gunnarsson PT, Winzell MS, Deacon CF, Larsen MO, Jelic K, Carr RD, Ahrèn B (2006) Glucose-induced incretin hormone release and inactivation are differently modulated by oral fat and protein in mice. Endocrinology 147:3173–3180

    CAS  Google Scholar 

  120. Demuth HU, McIntosh CH, Pederson RA (2005) Type 2diabetes—therapy with dipeptidyl peptidase IV inhibitors. Biochim Biophys Acta 1751:33–44

    CAS  Google Scholar 

  121. Deacon CF (2005) What do we know about the secretion and degradation of incretin hormones? Regul Pept 128:117–124

    CAS  Google Scholar 

  122. Kim W, Egan JM (2008) The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol Rev 60:470–512

    CAS  Google Scholar 

  123. Kalra S (2011) Emerging role of dipeptidyl peptidase-IV (DPP-4) inhibitor vildagliptin in the management of type 2 diabetes. J Assoc Physicians India 59:237–245

    Google Scholar 

  124. Addison D, Aguilar D (2011) Diabetes and cardiovascular disease: the potential benefit of incretin-based therapies. Curr Atheroscler Rep 13:115–122

    CAS  Google Scholar 

  125. Holst JJ, Deacon CF (2004) Glucagon-like peptide 1 and inhibitors of dipeptidyl peptidase IV in the treatment of type 2 diabetes mellitus. Curr Opin Pharmacol 4:589–596

    CAS  Google Scholar 

  126. Thornberry NA, Gallwitz B (2009) Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4). Best Pract Res Clin Endocrinol Metab 23:479–486

    CAS  Google Scholar 

  127. Thoma R, Löffler B, Stihle M, Huber W, Ruf A, Hennig M (2003) Structure basis of proline specific exopeptidase activity as observed in human dipeptidyl peptidase-IV. Structure 11:947–959

    CAS  Google Scholar 

  128. Rajput R (2009) Dipeptidyl Peptidase-IV Inhibitors: a new drug in the Therapeutic Armamentarium for treatment of Type 2 Diabetes Mellitus. J Indian Acad Clin Med 10:128–133

    Google Scholar 

  129. Deacon CF (2007) Incretin-based treatment of type 2 diabetes: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Diabetes Obes Metab 9:23–31

    CAS  Google Scholar 

  130. Weber AE (2004) Dipeptidyl peptidase IV inhibitors for the treatment of diabetes. J Med Chem 47:4135–4141

    CAS  Google Scholar 

  131. Deacon CF, Ahren B, Holst JJ (2004) Inhibitors of dipeptidyl peptidase-IV: a novel approach for the prevention and treatment of Type 2 diabetes? Expert Opin Investig Drugs 13:1091–1102

    CAS  Google Scholar 

  132. Herman GA, Bergman A, Stevens C (2006) Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab 91:4612–4619

    CAS  Google Scholar 

  133. Estrada-Salas PA, Montero-Moran GM, Martinez-Cuevas PP, Gonzalez C, Barba de la Rosa AP (2014) Characterization of antidiabetic and antihypertensive properties of canary seed (Phalaris canariensis L.) peptides. J Agric Food Chem 62(2):427–433

    CAS  Google Scholar 

  134. Pieter BJW (2006) Protein hydrolysate enriched in peptides inhibiting DPP-IV and their use. WO 2006/068480 200 (Patent)

  135. Green BD, Flatt PR, Bailey CJ (2006) Dipeptidyl peptidase IV (DPP IV) inhibitors: a newly emerging drug class for the treatment of type 2 diabetes. Diabetes Vasc Dis Res 3:159–165

    Google Scholar 

  136. Zhu CF, Li GZ, Peng HB, Zhang F, Chen Y, Li Y (2010) Treatment with marine collagen peptides modulates glucose and lipid metabolism in Chinese patients with type 2 diabetes mellitus. Appl Physiol Nutr Metab 35:797–804

    CAS  Google Scholar 

  137. Guerard F, Decourcelle N, Sabourin C, Floch-Laizet C, Le Grel L, Le Floch P, Gourlay F, Le Delezir R, Jaouen P, Bourseau P (2010) Recent developments of marine ingredients for food and nutraceutical applications: a review. Journal des Sciences Halieutiques et Aquatiques 2:21–27

    Google Scholar 

  138. Tominaga Y, Yokota S, Tanaka H et al (2012) Inventors Kaneka Corporation, assignee. Dipeptidyl peptidase-4 inhibitor. United States US 2012 0189611 (Patent)

  139. Silva-Sánchez C, de la Rosa APB, León-Galván MF (2008) Bioactive peptides in amaranth (Amaranthus hypo-chondriacus) seed. J Agric Food Chem 56:1233–1240

    Google Scholar 

  140. Hsu KC, Tung YS, Huang SL Jao CL (2013) Dipeptidyl peptidase-IV inhibitory activity of peptides in porcine skin gelatin hydrolysates. In Hernández-Ledesma B (ed) Bioactive food peptides in health and disease, pp 205–218. doi:10.5772/51264

  141. Dziuba M, Dziuba B, Iwaniak A (2009) Milk proteins as precursors of bioactive peptides. Acta Sci Pol Technol Aliment 8:71–90

    CAS  Google Scholar 

  142. Boots J (2006) Inventor Campina Nederland Holding BV assignee. Protein hydrolysates enriched in peptides inhibiting DPP IV and thier use. WO 2006/068480 200 (Patent)

  143. Nongonierma AB, FitzGerald RJ (2014) Susceptibility of milk protein derived peptides to dipeptidyl peptides IV (DPP-IV) hydrolysis. Food Chem 145:845–852

    CAS  Google Scholar 

  144. Silveira ST, Martínez-Maqueda D, Recio I, Hernández-Ledesma B (2013) Dipeptidyl peptidase-IV inhibitory peptides generated by tryptic hydrolysis of a whey protein concentrate rich in β-lactoglobulin. Food Chem 141:1072–1077

    CAS  Google Scholar 

  145. Tremblay A, Gilbert JA (2009) Milk products, insulin resistance syndrome and type 2 diabetes. J Am Coll Nutr 28(Suppl 1):91S–102S

    CAS  Google Scholar 

  146. Phelan M, Aisling A, FitzGerald RJ, O’Brien NM (2009) Casein-derived bioactive peptides: biological effects, industrial uses, safety aspects and regulatory status. Int Dairy J 19:643–654

    CAS  Google Scholar 

  147. Gill I, López-Fandiño R, Jorba X, Vulfson EN (1996) Biologically active peptides and enzymatic approaches to their production. Enzyme Microb Technol 18:163–183

    CAS  Google Scholar 

  148. Madureira AR, Tavares T, Gomes MP, Malcata FX (2010) Physiological properties of bioactive peptides obtain from whey proteins. J Dairy Sci 93:437–455

    CAS  Google Scholar 

  149. Kilara A, Panyam D (2003) Peptides from milk proteins and their properties. Crit Rev Food Sci Nut 43:607–633

    CAS  Google Scholar 

  150. Korhonen H, Pihlanto A (2003) Food-derived bioactive peptides-opportunities for designing future foods. Curr Pharm Des 9:1297–1308

    CAS  Google Scholar 

  151. Haque E, Chand R, Kapila S (2008) Biofunctional properties of bioactive peptides of milk origin. Food Rev Int 25:28–43

    Google Scholar 

  152. Urista CM, Fernández RA, Rodríguez FR, Cuenca AA, Jurado AT (2011) Review: production and functionality of active peptides from milk. Food Sci Technol Int 17:293–317

    CAS  Google Scholar 

  153. Juillard V, Le Bars D, Kunji ER, Konings WN, Gripon JC, Richard J (1995) Oligopeptides are the main source of nitrogen for Lactococcus lactis during growth in milk. Appl Environ Microbiol 61:3024–3030

    CAS  Google Scholar 

  154. Christensen JE, Dudley EG, Pederson JA, Steele JL (1999) Peptidases and amino acid catabolism in lactic acid bacteria. Antonie Van Leeuwenhoek 76:217–246

    CAS  Google Scholar 

  155. Alsayadi M, Jawfi AL et al (2014) Evaluation of anti-hyperglycemic and anti-hyperlipidemic activities of water kefir as probiotic on streptozotocin-induced diabetic wistar rats. J Diabetes Mellit 4:85–95

    CAS  Google Scholar 

  156. Teruya K, Yamashita M et al (2002) Fermented milk, Kefram-Kefir enhances glucose uptake into insulin-responsive muscle cells. Cytotechnology 40:107–116

    CAS  Google Scholar 

  157. Ostadrahimi A, Taghizadeh A, Mobasseri M, Farrin N, Payahoo L, Gheshlaghi ZB, Vahedjabbari M (2015) Effect of probiotic fermented milk (Kefir) on glycemic control and lipid profile in type 2 diabetic patients: a randomized double-blind placebo-controlled clinical trial. Iran J Public Health 44:228–237

    Google Scholar 

  158. Maeda H, Zhu X, Mitsuoka T (2004) Effects of an exopolysaccharide (kefiran) from Lactobacillus kefiranofaciens on blood glucose in KKAy mice and constipation in SD rats induced by a low-fiber diet. Biosci Microflora 23:149–153

    CAS  Google Scholar 

  159. Yi N, Hwang JY, Han JS (2009) Hypoglycemic effect of fermented soymilk extract in STZ-induced diabetic mice. J Food Sci Nutr 14:8–13

    CAS  Google Scholar 

  160. Yadav H, Jain S, Sinha PR (2007) Antidiabetic effect of probiotic dahi containing Lactobacillus acidophilus and Lactobacillus casei in high fructose fed rats. Nutrition 23:62–68

    Google Scholar 

  161. Kim SK, Wijesekara I (2010) Development and biological activities of marine-derived bioactive peptides: a review. J Funct Foods 2:1–9

    CAS  Google Scholar 

  162. Pedroche J, Yust MM, Lqari H, Megias C, Girón-Calle J, Alaiz M (2007) Obtaining of Brassica carinata protein hydrolysates enriched in bioactive peptides using immobilized digestive proteases. Food Res Int 40:931–938

    CAS  Google Scholar 

  163. Manders RJF, Hansen D, Zorenc AHG, Dendale P, Kloek J, Saris WHM, van Loon LJC (2014) Protein co-ingestion strongly increases postprandial insulin secretion in type 2 diabetes patients. J Med Food 17:758–763

    CAS  Google Scholar 

  164. Méric E, Lemieux S, Turgeon SL, Bazinet L (2014) Insulin and glucose responses after ingestion of different loads and forms of vegetable or animal proteins in protein enriched fruit beverages. J Funct Foods 10:95–103

    Google Scholar 

  165. Goudarzi M, Madadlou A (2013) Influence of whey protein and its hydrolysate on prehypertension and postprandial hyperglycaemia in adult men. Int Dairy J 33:62–66

    CAS  Google Scholar 

  166. Jonker JT, Wijngaarden MA et al (2011) Effect of low doses of casein hydrolysate on post-challenge glucose and insulin levels. Eur J Intern Med 22:245–248

    CAS  Google Scholar 

Download references

Acknowledgments

The authors thank the Director of NDRI for supporting the work. There are no conflicts of interest whatsoever among the authors.

Author information

Authors and Affiliations

  1. Dairy Microbiology Division, National Dairy Research Institute, Karnal, 132 001, India

    Prasad Patil, Surajit Mandal, Sudhir Kumar Tomar & Santosh Anand

Authors
  1. Prasad Patil
    View author publications

    You can also search for this author inPubMed Google Scholar

  2. Surajit Mandal
    View author publications

    You can also search for this author inPubMed Google Scholar

  3. Sudhir Kumar Tomar
    View author publications

    You can also search for this author inPubMed Google Scholar

  4. Santosh Anand
    View author publications

    You can also search for this author inPubMed Google Scholar

Corresponding author

Correspondence to Surajit Mandal.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Patil, P., Mandal, S., Tomar, S.K. et al. Food protein-derived bioactive peptides in management of type 2 diabetes. Eur J Nutr 54, 863–880 (2015). https://doi.org/10.1007/s00394-015-0974-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00394-015-0974-2

Keywords